Skip to search formSkip to main contentSkip to account menu

CF101

Known as: CF-101, cf 101 
National Institutes of Health

Related topics

Related topics

2 relations

Broader (1)

Adenosine
analogs & derivatives

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2019
Review
2019
An update on pathogenesis of psoriatic arthritis and potential therapeutic targets
ABSTRACT Introduction: Innate immune response and bone remodeling are key factors contributing to the pathogenesis of psoriatic… 
Review
2017
Review
2017
Small molecule therapy for managing moderate to severe psoriatic arthritis
ABSTRACT Introduction: The majority of psoriatic arthritis (PsA) patients experience a good clinical response to conventional… 
2016
2016
Treatment of Plaque-Type Psoriasis With Oral CF101: Data from a Phase II/III Multicenter, Randomized, Controlled Trial.
BACKGROUND CF101, an adenosine A3 receptor agonist, is an orally bioavailable small molecule drug presenting an anti-psoriatic… 
Review
2014
Review
2014
Potential for Developing Purinergic Drugs for Gastrointestinal Diseases
Abstract:Treatments for inflammatory bowel disease (IBD), irritable bowel syndrome (IBS), functional dyspepsia, or motility… 
Review
2014
Review
2014
Purinergic Receptors in Ocular Inflammation
Inflammation is a complex process that implies the interaction between cells and molecular mediators, which, when not properly… 
Highly Cited
2012
Highly Cited
2012
Treatment of plaque‐type psoriasis with oral CF101: data from an exploratory randomized phase 2 clinical trial
Aims  CF101 demonstrated a marked anti‐inflammatory effect in Phase 2 studies conducted in patients with rheumatoid arthritis and… 
2010
2010
Purines 2010: Adenine Nucleosides and Nucleotides in Biomedicine
The rodent P2X7k splice variant, which utilizes a different exon 1 and is expressed in both wild type and the Glaxo P2X7−/−mice… 
Highly Cited
2009
Highly Cited
2009
Induction of an antiinflammatory effect and prevention of cartilage damage in rat knee osteoarthritis by CF101 treatment.
OBJECTIVE Studies have suggested that rheumatoid arthritis (RA) and osteoarthritis (OA) share common characteristics. The highly… 
Review
2009
Review
2009
A3 adenosine receptor: pharmacology and role in disease.
The study of the A(3) adenosine receptor (A(3)AR) represents a rapidly growing and intense area of research in the adenosine… 
2006
2006
A phase II, multi-center study of a new non-cytotoxic A3 adenosine receptor agonist CF101, dose-finding (randomized blinded) in patients (pts) with refractory metastatic colorectal cancer.
13082 Background: The A3 adenosine Gi protein-coupled receptor is highly expressed in malignant compared to normal cells… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)